Adverum Biotechnologies Inc (ADVM)

7.32 -0.25 (-3.30%) USD  |  NASDAQ  |  Nov 14, 12:29
More

Adverum Biotechnologies Research and Development Expense (Quarterly): 20.44M for Sept. 30, 2024

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.
Date Value
September 30, 2024 20.44M
June 30, 2024 17.10M
March 31, 2024 15.41M
December 31, 2023 15.28M
September 30, 2023 20.74M
June 30, 2023 20.60M
March 31, 2023 21.06M
December 31, 2022 22.20M
September 30, 2022 23.85M
June 30, 2022 30.26M
March 31, 2022 22.96M
December 31, 2021 22.52M
September 30, 2021 24.07M
June 30, 2021 22.61M
March 31, 2021 19.98M
December 31, 2020 22.73M
September 30, 2020 16.65M
June 30, 2020 19.18M
March 31, 2020 14.75M
December 31, 2019 11.37M
September 30, 2019 9.944M
June 30, 2019 8.97M
March 31, 2019 10.13M
December 31, 2018 11.64M
Date Value
September 30, 2018 14.48M
June 30, 2018 11.22M
March 31, 2018 12.79M
December 31, 2017 12.01M
September 30, 2017 10.27M
June 30, 2017 8.492M
March 31, 2017 9.061M
December 31, 2016 7.898M
September 30, 2016 8.362M
June 30, 2016 7.955M
March 31, 2016 7.455M
December 31, 2015 7.192M
September 30, 2015 7.523M
June 30, 2015 5.126M
March 31, 2015 5.621M
December 31, 2014 7.226M
September 30, 2014 5.746M
June 30, 2014 3.094M
March 31, 2014 0.91M
December 31, 2013 0.739M
September 30, 2013 0.55M
June 30, 2013 0.661M
March 31, 2013 0.201M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

11.37M
Minimum
Dec 2019
30.26M
Maximum
Jun 2022
20.19M
Average
20.67M
Median

Research and Development Expense (Quarterly) Benchmarks

EyePoint Pharmaceuticals Inc 29.82M
Cassava Sciences Inc 17.68M
Regenxbio Inc 54.43M
Editas Medicine Inc 47.64M
Apellis Pharmaceuticals Inc 88.57M